Sodium-Glucose Cotransporter-2 Inhibitors in CKD: Is it Time to Update the Guideline Recommendations for Broader Cardiorenal Protection?

Kidney International Reports 2026 Open access

Read full text
Authors: Panagiotis I. Georgianos, Vasilios Vaios, Athanasios K. Roumeliotis, Vassilios Liakopoulos
DOI: 10.1016/j.ekir.2026.106361
Cited by: 0
References: 7

Abstract

Sodium-glucose cotransporter 2 inhibitors (SGLT2is) were originally developed for the improvement of glycemic control in patients with type 2 diabetes mellitus (T2D). This initial landscape was substantially modified after the discovery that the most impressive action of SGLT2is is the reduction in the risk of cardiorenal events.1 In a triad of landmark trials conducted specifically in patients with chronic kidney disease (CKD), relative to placebo, SGLT2is reduced the risk of kidney failure, or death from renal and cardiovascular causes.

Fields of Study & Subjects

Diabetes Treatment and Management Chronic Kidney Disease and Diabetes Acute Kidney Injury Research

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
106361–106361
Publication date
11 February 2026
Language
EN